Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Prices Offering of Senior Notes

NEW YORK (GenomeWeb News) – Affymetrix late on Tuesday announced the pricing of its $105 million offering of senior convertible notes.

The offering of the 4 percent convertible senior notes due 2019 had been previously announced on Monday. The notes will be convertible into Affy's common stock at an initial conversion rate of 170.0319 shares per $1,000 principal amount of notes, subject to adjustment. The conversion rate is equivalent to an initial conversion price of about $5.88 per share, representing a premium of 25 percent to the last reported sale of Affy's stock on the Nasdaq on June 19, when its shares closed at $4.71.

Affy will use net proceeds from the offering to partly fund its $315 million acquisition of eBioscience.

Citigroup and Morgan Stanley are acting as joint book-running managers on the offering. Bank of America Merrill Lynch and RW Baird are co-managers. Affy is granting the offering's underwriters an option to purchase up to $10 million aggregate principal amount of additional notes to cover any over-allotments.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.